Mr. Mike Piccinino reports

HELIUS MEDICAL TECHNOLOGIES, INC. JOINS RUSSELL 3000 INDEX, RUSSELL 2000 INDEX AND RUSSELL MICROCAP INDEX

Helius Medical Technologies Inc. has been added to the Russell 3000 Index, Russell 2000 Index and Russell Microcap Index. The company's inclusion occurred as part of the annual reconstitution by FTSE Russell of its U.S. equity indexes and will become effective today after the U.S. market opens.

"Helius Medical is excited to have been added to these Russell indexes, following our recent uplisting to Nasdaq on April 11," said Philippe Deschamps, Helius's president, chief executive officer and chairman. "Our inclusion in these indexes represents another important step towards increasing Helius's visibility in the public markets."

Membership in the Russell 3000 Index and Russell Microcap Index is determined primarily by objective, market-capitalization rankings and style attributes, and remains in place for a minimum of one year. Membership in the Russell 3000 Index results in automatic inclusion in either the large-cap Russell 1000 Index or small-cap Russell 2000 Index. In connection with their membership in each Russell index, companies are also included in the appropriate growth and value style indexes.

About Helius Medical Technologies Inc.

Helius Medical Technologies is a neurotech company focused on neurological wellness. The company's purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain's ability to heal itself. The company's first product in development is the Portable Neuromodulation Stimulator (PoNS).

About the PoNS device and PoNS treatment

The Portable Neuromodulation Stimulator (PoNS) is an investigational, non-invasive, medical device. PoNS treatment is the first and only tongue-delivered neuromodulation that combines stimulation of cranial nerves with physical and cognitive therapy to restore lost neurological function. The company's trials investigating the PoNS in traumatic brain injury are more fully discussed in the company's disclosure materials, including its annual report on Form 10-K and other filings with the United States Securities and Exchange Commission.